GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Additional Paid-In Capital

BLRX (BioLine Rx) Additional Paid-In Capital : $353.01 Mil(As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Additional Paid-In Capital?


BioLine Rx's quarterly additional paid-in capital declined from Mar. 2024 ($355.48 Mil) to Jun. 2024 ($352.43 Mil) but then increased from Jun. 2024 ($352.43 Mil) to Sep. 2024 ($353.01 Mil).

BioLine Rx's annual additional paid-in capital declined from Dec. 2021 ($339.35 Mil) to Dec. 2022 ($338.98 Mil) but then increased from Dec. 2022 ($338.98 Mil) to Dec. 2023 ($355.48 Mil).

BioLine Rx Additional Paid-In Capital Historical Data

The historical data trend for BioLine Rx's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Additional Paid-In Capital Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 265.94 279.24 339.35 338.98 355.48

BioLine Rx Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 345.46 355.48 355.48 352.43 353.01

BioLine Rx Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

BioLine Rx Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Additional Paid-In Capital
Comparable Companies
XTAE:CGEN XTAE:SLGN XTAE:BONS XTAE:PPBT XTAE:GFC-M XTAE:EVGN XTAE:DNA XTAE:CBI XTAE:MTLF XTAE:CANF OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BLRX:Israel YP2A:Germany
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
Website
https://www.biolinerx.com
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.